Rhopressa

Manufacturer
Alcon Laboratories, Inc.
Effective date
2026-01-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
17
Source
full-release
Hydrated at
2026-05-31 21:56:39

Label at a glance#

ProductRhopressa
Active ingredientNETARSUDIL MESYLATE
Label structure15 sections

Indications and uses

RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and administration

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart [see Patient Counseling Inform...

Storage and handling

RHOPRESSA ® (netarsudil ophthalmic solution) 0.02% (0.2 mg per mL) is supplied sterile in opaque white low density polyethylene bottles and tips with white polypropylene caps. 2.5 mL fill in a 4 mL container NDC # 70727-497-25 Storage: Store at 2°C to 8°C (36°F to 46°F) until opened. After opening, the product may be kept at 2°C to 25°C (36°F to 77°F) for up to 6 weeks. If after opening the product is kept refrige...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart [see Patient Counseling Information (17)].

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Ophthalmic solution containing netarsudil 0.02% (0.2 mg/mL).

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Epithelial Corneal Edema

SPL UNCLASSIFIED SECTION

Epithelial corneal edema, described as honeycomb or bullous, has been reported in some patients with pre-existing corneal stromal edema or following ocular procedures that could affect corneal endothelial function. Epithelial corneal edema typically resolves upon discontinuation of RHOPRESSA. Advise patients to notify their physician if they experience eye pain or decreased vision while using RHOPRESSA [see Adverse Reactions (6.2) and Patient Counselling Information (17)].

5.2 Bacterial Keratitis

SPL UNCLASSIFIED SECTION

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface [see Patient Counseling Information (17)].

5.3 Use with Contact Lenses

SPL UNCLASSIFIED SECTION

Contact lenses should be removed prior to instillation of RHOPRESSA and may be reinserted 15 minutes following its administration.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Clinical Trials Experience

SPL UNCLASSIFIED SECTION

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA dosed once daily was conjunctival hyperemia which was reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) ocular adverse reactions reported were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

Corneal Verticillata

Corneal verticillata occurred in approximately 20% of the patients in controlled clinical studies. The corneal verticillata seen in RHOPRESSA-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes in patients. Most corneal verticillata resolved upon discontinuation of treatment.

6.2 Postmarketing Experience

POSTMARKETING EXPERIENCE SECTION

The following adverse reactions have been identified during postmarketing use of RHOPRESSA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Eye disorders: Epithelial corneal edema has been reported in some patients with pre-existing corneal stromal edema or following ocular procedures (that could affect corneal endothelial function) [see Warnings and Precautions (5.1)].

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are no available data on RHOPRESSA use in pregnant women to inform any drug associated risk; however, systemic exposure to netarsudil from ocular administration is low [see Clinical Pharmacology (12.3 )]. Intravenous administration of netarsudil to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at clinically relevant systemic exposures [see Data].

Data

Animal Data

Netarsudil administered daily by intravenous injection to rats during organogenesis caused abortions and embryofetal lethality at doses ≥0.3 mg/kg/day (126-fold the plasma exposure at the recommended human ophthalmic dose [RHOD], based on Cmax). The no-observed-adverse-effect-level (NOAEL) for embryofetal development toxicity was 0.1 mg/kg/day (40-fold the plasma exposure at the RHOD, based on Cmax).

Netarsudil administered daily by intravenous injection to rabbits during organogenesis caused embryofetal lethality and decreased fetal weight at 5 mg/kg/day (1480-fold the plasma exposure at the RHOD, based on Cmax). Malformations were observed at ≥3 mg/kg/day (1330-fold the plasma exposure at the RHOD, based on Cmax), including thoracogastroschisis, umbilical hernia and absent intermediate lung lobe. The NOAEL for embryofetal development toxicity was 0.5 mg/kg/day (214-fold the plasma exposure at the RHOD, based on Cmax).

8.2 Lactation

LACTATION SECTION

Risk Summary

There are no data on the presence of RHOPRESSA in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to netarsudil following topical ocular administration is low [see Clinical Pharmacology (12.3)], and it is not known whether measurable levels of netarsudil would be present in maternal milk following topical ocular administration.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RHOPRESSA and any potential adverse effects on the breast-fed child from RHOPRESSA.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 18 years have not been established.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

11 DESCRIPTION

DESCRIPTION SECTION

Netarsudil is a Rho kinase inhibitor. Its chemical name is (S)-4-(3-amino-1-(isoquinolin-6-yl-amino)-1-oxopropan-2-yl) benzyl 2,4-dimethylbenzoate dimesylate. The molecular formula of the free base is C28H27N3O3 and the molecular formula of the dimesylate is C30H35N3O9S2. The molecular weight of the free base is 453.54 and the molecular weight of the dimesylate is 645.74. The chemical structure is:

Netarsudil structural formula
Netarsudil structural formula

Netarsudil dimesylate is a light yellow-to-white powder that is freely soluble in water, soluble in methanol, sparingly soluble in dimethyl formamide, and practically insoluble in dichloromethane and heptane.

RHOPRESSA (netarsudil ophthalmic solution) 0.02% is supplied as a sterile, isotonic, buffered aqueous solution of netarsudil dimesylate with a pH of approximately 5 and an osmolality of approximately 295 mOsmol/kg. It is intended for topical application in the eye. Each mL of RHOPRESSA contains 0.2 mg of netarsudil (equivalent to 0.28 mg of netarsudil dimesylate). Benzalkonium chloride, 0.015%, is added as a preservative. The inactive ingredients are: boric acid, mannitol, sodium hydroxide to adjust pH, and water for injection.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork. The exact mechanism is unknown.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption

The systemic exposures of netarsudil and its active metabolite, AR-13503, were evaluated in 18 healthy subjects after topical ocular administration of RHOPRESSA 0.02% once daily (one drop bilaterally in the morning) for 8 days. There were no quantifiable plasma concentrations of netarsudil (lower limit of quantitation (LLOQ) 0.100 ng/mL) post dose on Day 1 and Day 8. Only one plasma concentration at 0.11 ng/mL for the active metabolite was observed for one subject on Day 8 at 8 hours post-dose.

Metabolism

After topical ocular dosing, netarsudil is metabolized by esterases in the eye.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of netarsudil. Netarsudil was not mutagenic in the Ames test, in the mouse lymphoma test, or in the in vivo rat micronucleus test. Studies to evaluate the effects of netarsudil on male or female fertility in animals have not been performed.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

RHOPRESSA 0.02% was evaluated in three randomized and controlled clinical trials, namely AR-13324-CS301 (NCT 02207491, referred to as Study 301), AR-13324-CS302 (NCT 02207621, referred to as Study 302), and AR-13324-CS304 (NCT 02558374, referred to as Study 304), in patients with open-angle glaucoma or ocular hypertension. Studies 301 and 302 enrolled subjects with baseline IOP lower than 27 mmHg and Study 304 enrolled subjects with baseline IOP lower than 30 mmHg. The treatment duration was 3 months in Study 301, 12 months in Study 302, and 6 months in Study 304.

The three studies demonstrated up to 5 mmHg reductions in IOP for subjects treated with RHOPRESSA 0.02% once daily in the evening. For patients with baseline IOP < 25 mmHg, the IOP reductions with RHOPRESSA 0.02% dosed once daily were similar to those with timolol 0.5% dosed twice daily (see Table 1). For patients with baseline IOP equal to or above 25 mmHg, however, RHOPRESSA 0.02% resulted in smaller mean IOP reductions at the morning time points than timolol 0.5% for study visits on Days 43 and 90; the difference in mean IOP reduction between the two treatment groups was as high as 3 mmHg, favoring timolol.

Table 1: Mean IOP Change from Baseline of Study Eye (mmHg) by Visit and Time

Study 301: Subjects with Baseline IOP < 25 mmHgStudy 301: Subjects with Baseline IOP < 25 mmHgStudy 301: Subjects with Baseline IOP >= 25 and < 27 mmHgStudy 301: Subjects with Baseline IOP >= 25 and < 27 mmHg
Study 302: Subjects with Baseline IOP < 25 mmHgStudy 302: Subjects with Baseline IOP < 25 mmHgStudy 302: Subjects with Baseline IOP >= 25 and < 27 mmHgStudy 302: Subjects with Baseline IOP >= 25 and < 27 mmHg
Study 304: Subjects with Baseline IOP < 25 mmHgStudy 304: Subjects with Baseline IOP < 25 mmHgStudy 304: Subjects with Baseline IOP >= 25 and < 30 mmHgStudy 304: Subjects with Baseline IOP >= 25 and < 30 mmHg

This table was produced based on the observed data from all randomized subjects who did not have major protocol violations. The treatment differences and two-sided CIs for comparing Rhopressa QD vs Timolol BID 0.5% were based on Analysis of Covariance (ANCOVA) adjusted for baseline IOP.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

RHOPRESSA® (netarsudil ophthalmic solution) 0.02% (0.2 mg per mL) is supplied sterile in opaque white low density polyethylene bottles and tips with white polypropylene caps.

2.5 mL fill in a 4 mL container
NDC # 70727-497-25

Storage: Store at 2°C to 8°C (36°F to 46°F) until opened. After opening, the product may be kept at 2°C to 25°C (36°F to 77°F) for up to 6 weeks. If after opening the product is kept refrigerated at 2°C to 8°C (36°F to 46°F), then the product can be used until the expiration date stamped on the bottle. During shipment, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Handling the Container

Instruct patients to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see Warnings and Precautions (5.2)].

When to Seek Physician Advice

Advise patients that if they develop an intercurrent ocular condition (e.g., trauma, infection, or decreased vision with or without eye pain), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of RHOPRESSA.

Use with Contact Lenses

Advise patients that RHOPRESSA contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of RHOPRESSA and may be reinserted 15 minutes following its administration.

Use with Other Ophthalmic Drugs

Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes between applications.

Missed Dose

Advise patients that if one dose is missed, treatment should continue with the next dose in the evening.

© 2024 Alcon Inc.

U.S. Pat.: www.alconpatents.com
ALCON LABORATORIES, INC.
6201 South Freeway Fort Worth, Texas 76134 USA
1-800-757-9195
Alcon.medinfo@alcon.com

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70727-497-25

rhopressa ®
     (netarsudil ophthalmic
      solution) 0.02%

For topical application
in the eye


Sterile
Rx only


2.5 mL

Alcon

Usual dosage:
One drop in the affected
eye(s) once daily in the
evening.

Each mL Rhopressa®
ophthalmic solution contains:
Active: netarsudil mesylate
0.285 mg
Preservative:
benzalkonium chloride
0.15 mg
Inactives: mannitol, boric
acid, sodium hydroxide to
adjust pH and water for
injection.

Manufactured for:
ALCON LABORATORIES, INC.
Fort Worth, TX 76134 USA

U.S. Pat: www.alconpatents.com

Store at 2°C - 8°C
(36°F - 46°F) until opened.
After opening, the product
may be kept at 2°C - 25°C
(36°F - 77°F) for up to 6
weeks. If after opening the
product is kept refrigerated at
2°C - 8°C (36°F - 46°F), then
the product can be used until
the expiration date stamped
on the bottle. During
shipment, the bottle may be
maintained at temperatures
up to 40°C (104°F) for a
period not exceeding 14 days.

41079

Carton Label
Carton Label

NDC 70727-497-25       For topical application in the eye.

rhopressa ®
(netarsudil ophthalmic
      solution) 0.02%

Rx only
Sterile 

2.5 mL                    Alcon                    41077  

See carton for storage conditions.
Manufactured for:
Alcon Laboratories, Inc.
Fort Worth, TX 76134


LOT:
EXP:

Bottle Label
Bottle Label

NDC 70727-497-99

SAMPLE - Not for Resale

rhopressa ®
(netarsudil ophthalmic
      solution) 0.02%

For topical application in the eye

Sterile Rx only

2.5 mL

Alcon

Usual dosage:
One drop in the affected
eye(s) once daily in the
evening.

Each mL Rhopressa®
ophthalmic solution contains:
Active: netarsudil mesylate
0.285 mg
Preservative:
benzalkonium chloride
0.15 mg
Inactives: mannitol, boric
acid, sodium hydroxide to
adjust pH and water for
injection.

Manufactured for:
ALCON LABORATORIES, INC.
Fort Worth, TX 76134 USA

U.S. Pat: www.alconpatents.com

Store at 2°C - 8°C
(36°F - 46°F) until opened.
After opening, the product
may be kept at 2°C - 25°C
(36°F - 77°F) for up to 6
weeks. If after opening the
product is kept refrigerated at
2°C - 8°C (36°F - 46°F), then
the product can be used until
the expiration date stamped
on the bottle. During
shipment, the bottle may be
maintained at temperatures
up to 40°C (104°F) for a
period not exceeding 14 days.

41080

Sample Carton Label
Sample Carton Label

NDC 70727-497-99   SAMPLE - Not for Resale    For topical application in the eye.

rhopressa ®
(netarsudil ophthalmic
      solution) 0.02%

Rx only
Sterile 

2.5 mL                    Alcon                    41078

See carton for
storage conditions.
Manufactured for:
Alcon Laboratories, Inc.
Fort Worth, TX 76134


LOT:
EXP:

Sample Bottle Label
Sample Bottle Label

NDC 70727-497-25

rhopressa ®
     (netarsudil ophthalmic
      solution) 0.02%

For topical application
in the eye


Sterile
Rx only          
2.5 mL

Alcon

Usual dosage:
One drop in the affected eye(s) once
daily in the evening.

Each mL Rhopressa® ophthalmic solution
contains:
Active: netarsudil mesylate 0.285 mg
Preservative:
benzalkonium chloride
0.15 mg
Inactives: mannitol, boric acid, sodium
hydroxide toadjust pH and water for
injection.

ALCON LABORATORIES, INC.
Fort Worth, TX 76134 USA

U.S. Pat: www.alconpatents.com

Store at 2°C - 8°C (36°F - 46°F) until
opened. After opening, the product may
be kept at 2°C - 25°C (36°F - 77°F) for up
to 6 weeks. If after opening the product is
kept refrigerated at 2°C - 8°C (36°F - 46°F),
then the product can be used until the
expiration date stamped on the bottle.
During shipment, the bottle may be
maintained at temperatures up to 40°C
(104°F) for a period not exceeding 14 days.

300069021-1224

Carton Label
Carton Label

NDC 70727-497-25       For topical application in the eye.

rhopressa ®
(netarsudil ophthalmic
      solution) 0.02%

Rx only
Sterile 

2.5 mL                    Alcon                    

See carton for storage conditions.

Alcon Laboratories, Inc.
Fort Worth, TX 76134


LOT:           EXP.:

300069075
1224

Bottle Label
Bottle Label

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70727-497-99

SAMPLE - Not for Resale

rhopressa ®
      (netarsudil ophthalmic
      solution) 0.02%

For topical application
in the eye


Sterile
Rx only         
2.5 mL

Alcon

Usual dosage:
One drop in the affected
eye(s) once daily in the
evening.

Each mL Rhopressa®
ophthalmic solution contains:
Active: netarsudil mesylate
0.285 mg
Preservative:
benzalkonium chloride
0.15 mg
Inactives: mannitol, boric
acid, sodium hydroxide to
adjust pH and water for
injection.

ALCON LABORATORIES, INC.
Fort Worth, TX 76134 USA

U.S. Pat: www.alconpatents.com

Store at 2°C - 8°C
(36°F - 46°F) until opened.
After opening, the product may
be kept at 2°C - 25°C
(36°F - 77°F) for up to 6 weeks.
If after opening the product is
kept refrigerated at 2°C - 8°C
(36°F - 46°F), then the product
can be used until the
expiration date stamped on the
bottle. During shipment, the
bottle may be maintained at
temperatures up to 40°C
(104°F) for a period not
exceeding 14 days.

300069020-1124

Sample Carton Label
Sample Carton Label

NDC 70727-497-99   SAMPLE - Not for Resale    For topical application in the eye.

rhopressa ®
     (netarsudil ophthalmic
      solution) 0.02%

Rx only
Sterile      2.5 mL                    Alcon                   

See carton for
storage conditions.

Alcon Laboratories, Inc.
Fort Worth, TX 76134 USA


LOT:            EXP.:

300069074
1124

Sample Bottle Label
Sample Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1992868netarsudil 0.02 % Ophthalmic SolutionPSN17
1992873Rhopressa 0.02 % Ophthalmic SolutionPSN17
1992873netarsudil 0.2 MG/ML Ophthalmic Solution [Rhopressa]SBD17
1992868netarsudil 0.2 MG/ML Ophthalmic SolutionSCD17
1992868netarsudil 0.02 % Ophthalmic SolutionSY17
1992868netarsudil 0.2 MG/ML (as netarsudil dimesylate 0.28 MG/ML) Ophthalmic SolutionSY17
1992873Rhopressa 0.02 % Ophthalmic SolutionSY17
1992873Rhopressa 0.2 MG/ML (as netarsudil dimesylate 0.28 MG/ML) Ophthalmic SolutionSY17
1992873Rhopressa 0.2 MG/ML Ophthalmic SolutionSY17

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NETARSUDIL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180830

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeDataBar Stacked(01)00370727497255GTIN-14: 00370727497255
GTIN-12: 370727497255
UPC-A: 370727497255
EAN-13: 0370727497255
GTIN storage (14 digits): 00370727497255
bottlelabel.jpg
BarcodeEAN-130370727497255GTIN-13: 0370727497255
EAN-13: 0370727497255
GTIN-12: 370727497255
UPC-A: 370727497255
GTIN storage (14 digits): 00370727497255
cartonlabel.jpg
Data codeData Matrix41077label-25.jpg
Data codeData Matrix41078label-99.jpg
Data codeData Matrix300069020samplecartonlabel.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
203382e3-d801-4f70-866f-ebe316583560Product name120190624
dc99c89e-d489-4ded-8898-111a91f10877Product name120180221

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70727-497-25Rhopressa1 in 1 CARTONSOLUTION/ DROPS117
70727-497-25Rhopressa2.5 mL in 1 BOTTLESOLUTION/ DROPS2.517
70727-497-99Rhopressa1 in 1 CARTONSOLUTION/ DROPS117
70727-497-99Rhopressa2.5 mL in 1 BOTTLESOLUTION/ DROPS2.517

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70727-497-25ML - Milliliter70727-4974820c538-7f5c-4eaf-9ba9-795606dad8ff12018-04-19

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70727-49770727-497-25, 70727-497-99

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
162025-09-29legacy-cache2026-10-21 23:53:11

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N208254-001RHOPRESSANETARSUDIL MESYLATEEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18

Orange Book patents#

Current patent rows page 1 of 1 · 15 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N208254-001105329932026-07-11U-15242020-03-30
N208254-001108828402026-07-11U-15242021-01-22
N208254-001110214562026-07-11U-15242021-06-28
N208254-00184503442026-07-11U-1524Drug substance, Drug product2017-12-21
N208254-00190965692026-07-11U-1524Drug substance, Drug product2017-12-21
N208254-001101740172030-01-27U-1524Drug substance, Drug product2019-03-28
N208254-001106548442030-01-27U-1524Drug substance, Drug product2020-06-10
N208254-001110280812030-01-27U-15242021-06-28
N208254-001116187482030-01-27U-15242023-04-21
N208254-00183948262030-11-10U-1524Drug substance, Drug product2017-12-21
N208254-001105889012034-03-14U-1524Drug substance, Drug product2020-04-15
N208254-001110203852034-03-14U-15242024-07-12
N208254-001111855382034-03-14Drug product2021-12-16
N208254-00194150432034-03-14Drug substance2017-12-21
N208254-00199313362034-03-14U-1524Drug substance, Drug product2018-04-11

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18c2088c7a36db…
2026-09-14 22:38:342026-08N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1884e616aacf4f…
2026-08-18 06:07:402026-07N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1887673890dc5c…
2021-03-12 10:30 UTC2021-03N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-183f01610625f2…
2019-09-15 20:21 UTC2019-09N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18b00525d2431f…
2019-07-19 19:46 UTC2019-07N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-183f0d92c62455…
2023-05-13 08:27 UTC2023-05N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-18053a50430f4f…
2023-01-26 05:58 UTC2023-01N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N208254-001RHOPRESSAEQ 0.02% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-183a93d1ddd44b…

Observed Orange Book patent history#

Patent history page 1 of 15 · 569 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-10-15 13:18:302026-09N208254-001105329932026-07-11U-15242020-03-30c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001108828402026-07-11U-15242021-01-22c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001110214562026-07-11U-15242021-06-28c2088c7a36db…
2026-10-15 13:18:302026-09N208254-00184503442026-07-11U-1524Drug substance, Drug product2017-12-21c2088c7a36db…
2026-10-15 13:18:302026-09N208254-00190965692026-07-11U-1524Drug substance, Drug product2017-12-21c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001101740172030-01-27U-1524Drug substance, Drug product2019-03-28c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001106548442030-01-27U-1524Drug substance, Drug product2020-06-10c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001110280812030-01-27U-15242021-06-28c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001116187482030-01-27U-15242023-04-21c2088c7a36db…
2026-10-15 13:18:302026-09N208254-00183948262030-11-10U-1524Drug substance, Drug product2017-12-21c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001105889012034-03-14U-1524Drug substance, Drug product2020-04-15c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001110203852034-03-14U-15242024-07-12c2088c7a36db…
2026-10-15 13:18:302026-09N208254-001111855382034-03-14Drug product2021-12-16c2088c7a36db…
2026-10-15 13:18:302026-09N208254-00194150432034-03-14Drug substance2017-12-21c2088c7a36db…
2026-10-15 13:18:302026-09N208254-00199313362034-03-14U-1524Drug substance, Drug product2018-04-11c2088c7a36db…
2026-09-14 22:38:342026-08N208254-001105329932026-07-11U-15242020-03-3084e616aacf4f…
2026-09-14 22:38:342026-08N208254-001108828402026-07-11U-15242021-01-2284e616aacf4f…
2026-09-14 22:38:342026-08N208254-001110214562026-07-11U-15242021-06-2884e616aacf4f…
2026-09-14 22:38:342026-08N208254-00184503442026-07-11U-1524Drug substance, Drug product2017-12-2184e616aacf4f…
2026-09-14 22:38:342026-08N208254-00190965692026-07-11U-1524Drug substance, Drug product2017-12-2184e616aacf4f…
2026-09-14 22:38:342026-08N208254-001101740172030-01-27U-1524Drug substance, Drug product2019-03-2884e616aacf4f…
2026-09-14 22:38:342026-08N208254-001106548442030-01-27U-1524Drug substance, Drug product2020-06-1084e616aacf4f…
2026-09-14 22:38:342026-08N208254-001110280812030-01-27U-15242021-06-2884e616aacf4f…
2026-09-14 22:38:342026-08N208254-001116187482030-01-27U-15242023-04-2184e616aacf4f…
2026-09-14 22:38:342026-08N208254-00183948262030-11-10U-1524Drug substance, Drug product2017-12-2184e616aacf4f…
2026-09-14 22:38:342026-08N208254-001105889012034-03-14U-1524Drug substance, Drug product2020-04-1584e616aacf4f…
2026-09-14 22:38:342026-08N208254-001110203852034-03-14U-15242024-07-1284e616aacf4f…
2026-09-14 22:38:342026-08N208254-001111855382034-03-14Drug product2021-12-1684e616aacf4f…
2026-09-14 22:38:342026-08N208254-00194150432034-03-14Drug substance2017-12-2184e616aacf4f…
2026-09-14 22:38:342026-08N208254-00199313362034-03-14U-1524Drug substance, Drug product2018-04-1184e616aacf4f…
2026-08-18 06:07:402026-07N208254-001105329932026-07-11U-15242020-03-30caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-001108828402026-07-11U-15242021-01-22caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-001110214562026-07-11U-15242021-06-28caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-00184503442026-07-11U-1524Drug substance, Drug product2017-12-21caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-00190965692026-07-11U-1524Drug substance, Drug product2017-12-21caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-001101740172030-01-27U-1524Drug substance, Drug product2019-03-28caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-001106548442030-01-27U-1524Drug substance, Drug product2020-06-10caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-001110280812030-01-27U-15242021-06-28caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-001116187482030-01-27U-15242023-04-21caaa826d4ba7…
2026-08-18 06:07:402026-07N208254-00183948262030-11-10U-1524Drug substance, Drug product2017-12-21caaa826d4ba7…

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
CapturedEditionApplication-productExclusivity codeExpirationSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N208254-001NCE2022-12-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N208254-001NCE2022-12-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N208254-001NCE2022-12-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N208254-001NCE2022-12-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N208254-001NCE2022-12-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N208254-001NCE2022-12-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N208254-001NCE2022-12-1887673890dc5c…
2021-03-12 10:30 UTC2021-03N208254-001NCE2022-12-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N208254-001NCE2022-12-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11N208254-001NCE2022-12-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12N208254-001NCE2022-12-183f01610625f2…
2019-09-15 20:21 UTC2019-09N208254-001NCE2022-12-18b00525d2431f…
2019-07-19 19:46 UTC2019-07N208254-001NCE2022-12-18ea99ee380514…
2023-01-26 05:58 UTC2023-01N208254-001NCE2022-12-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N208254-001NCE2022-12-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N208254-001NCE2022-12-18f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N208254-001NCE2022-12-18e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N208254-001NCE2022-12-18cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RhopressaNETARSUDILAlcon Laboratories, Inc.7d4f0e3a-5b86-4c43-982a-813b22ae7e222026-01-20Warnings, Adverse reactionsExact identifier
ndc (package): 70727-497-25
ndc (package): 70727-497-99
ndc (product): 70727-497
ndc11 (package): 70727049725
ndc11 (package): 70727049799
spl id: 82acde68-4935-4dc9-82ff-9ff7f449f893
spl set id: 7d4f0e3a-5b86-4c43-982a-813b22ae7e22

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.